CTC
ACAD icon

Central Trust Company’s Acadia Pharmaceuticals ACAD Stock Holding History

Central Trust Company’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$1.07K – 1550
2025
Q3 		$1.07K Hold
50
– – ﹤0.01% 1324
2025
Q2 		$1.08K Hold
50
– – ﹤0.01% 1361
2025
Q1 		$831 Hold
50
– – ﹤0.01% 1390
2024
Q4 		$918 Hold
50
– – ﹤0.01% 1387
2024
Q3 		$769 Hold
50
– – ﹤0.01% 1340
2024
Q2 		$813 Hold
50
– – ﹤0.01% 1349
2024
Q1 		$925 Hold
50
– – ﹤0.01% 1322
2023
Q4 		$1.57K Buy
+50
New +$1.19K ﹤0.01% 1304

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Central Trust Company's ACAD Position: Q4 2025 in Review

Central Trust Company sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 50 shares — an estimated $1.07K sold.

Central Trust Company first reported a position in ACAD in Q4 2023 and held it in 8 quarters. The position peaked at $1.57K in Q4 2023. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Central Trust Company reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Central Trust Company sold 50 Acadia Pharmaceuticals shares in Q4 2025, an estimated $1.07K.
  • Central Trust Company first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Central Trust Company's Acadia Pharmaceuticals position peaked at $1.57K in Q4 2023.
  • 336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Central Trust Company's 13F filing for Q4 2025, filed 2 Feb 2026.